Market Cap | 404.24M | P/E | 8.85 | EPS this Y | 9.80% | Ern Qtrly Grth | - |
Income | -153.16M | Forward P/E | -2.36 | EPS next Y | 5.10% | 50D Avg Chg | -7.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -8.00% |
Dividend | N/A | Price/Book | 0.83 | EPS next 5Y | - | 52W High Chg | -32.00% |
Recommedations | 1.40 | Quick Ratio | 16.60 | Shares Outstanding | 43.07M | 52W Low Chg | 32.00% |
Insider Own | 6.40% | ROA | -22.80% | Shares Float | 22.59M | Beta | 0.00 |
Inst Own | 102.47% | ROE | -31.37% | Shares Shorted/Prior | 1.68M/0.94M | Price | 10.27 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 321,240 | Target Price | 33.14 |
Oper. Margin | - | Earnings Date | May 9 | Volume | 108,186 | Change | -1.06% |
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Stifel | Buy | May 1, 24 |
BTIG | Buy | Apr 17, 24 |
JonesTrading | Buy | Apr 17, 24 |
HC Wainwright & Co. | Buy | Apr 16, 24 |
William Blair | Outperform | Apr 15, 24 |
HC Wainwright & Co. | Buy | Mar 14, 24 |
Wedbush | Outperform | Feb 15, 24 |
JonesTrading | Buy | Oct 6, 23 |
HC Wainwright & Co. | Buy | Aug 11, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Savill Corrine | Chief Business Offic.. Chief Business Officer | Feb 01 | Sell | 16.18 | 40,000 | 647,200 | 165,990 | 02/02/24 |
Savill Corrine | Chief Business Offic.. Chief Business Officer | Feb 01 | Option | 4.3 | 40,000 | 172,000 | 205,990 | 02/02/24 |
Savill Corrine | Chief Business Offic.. Chief Business Officer | Jan 29 | Sell | 14.09 | 40,000 | 563,600 | 165,990 | 01/30/24 |
Savill Corrine | Chief Business Offic.. Chief Business Officer | Jan 29 | Option | 4.3 | 40,000 | 172,000 | 205,990 | 01/30/24 |
Savill Corrine | Chief Business Offic.. Chief Business Officer | Jan 22 | Sell | 12.22 | 40,000 | 488,800 | 165,990 | 01/24/24 |
Savill Corrine | Chief Business Offic.. Chief Business Officer | Jan 22 | Option | 4.3 | 35,875 | 154,262 | 187,306 | 01/24/24 |
AHMED NADIM | President and CEO President and CEO | Dec 26 | Sell | 9.24 | 4,272 | 39,473 | 111,550 | 12/27/23 |
Jones Jeffrey Alan | Chief Medical Office.. Chief Medical Officer | Dec 21 | Sell | 8.50 | 1,860 | 15,810 | 56,191 | 12/22/23 |
SUMER JACQUELYN L | Chief Legal Officer Chief Legal Officer | Dec 21 | Sell | 8.50 | 1,400 | 11,900 | 44,133 | 12/22/23 |
Trigilio Jeffrey | Chief Financial Offi.. Chief Financial Officer | Dec 21 | Sell | 8.50 | 1,920 | 16,320 | 83,919 | 12/22/23 |
Michaelson Jennifer | Chief Scientific Off.. Chief Scientific Officer | Dec 21 | Sell | 8.50 | 1,145 | 9,732 | 87,582 | 12/22/23 |
Jones Jeffrey Alan | Chief Medical Office.. Chief Medical Officer | Dec 18 | Sell | 8.22 | 386 | 3,173 | 58,051 | 12/20/23 |
Michaelson Jennifer | Chief Scientific Off.. Chief Scientific Officer | Dec 18 | Sell | 8.22 | 238 | 1,956 | 88,727 | 12/20/23 |
SUMER JACQUELYN L | Chief Legal Officer Chief Legal Officer | Dec 18 | Sell | 8.22 | 290 | 2,384 | 45,533 | 12/20/23 |
Trigilio Jeffrey | Chief Financial Offi.. Chief Financial Officer | Dec 18 | Sell | 8.22 | 398 | 3,272 | 85,839 | 12/20/23 |
Trigilio Jeffrey | Chief Financial Offi.. Chief Financial Officer | Dec 12 | Sell | 7.81 | 1,926 | 15,042 | 86,237 | 12/13/23 |
Michaelson Jennifer | Chief Scientific Off.. Chief Scientific Officer | Dec 12 | Sell | 7.81 | 1,068 | 8,341 | 88,965 | 12/13/23 |
AHMED NADIM | President and CEO President and CEO | Jun 28 | Sell | 11.40 | 759 | 8,653 | 115,822 | 06/29/23 |
Michaelson Jennifer | Chief Development Of.. Chief Development Officer | May 12 | Sell | 8.78 | 193 | 1,695 | 90,686 | 05/16/23 |
Trigilio Jeffrey | Chief Financial Offi.. Chief Financial Officer | May 12 | Sell | 8.78 | 347 | 3,047 | 86,940 | 05/16/23 |
Trigilio Jeffrey | Chief Financial Offi.. Chief Financial Officer | Apr 12 | Sell | 10.22 | 318 | 3,250 | 87,685 | 04/14/23 |
Michaelson Jennifer | Chief Development Of.. Chief Development Officer | Apr 12 | Sell | 10.22 | 176 | 1,799 | 91,117 | 04/14/23 |
Michaelson Jennifer | See Remarks See Remarks | Nov 25 | Option | 4.3 | 4,000 | 17,200 | 57,031 | 11/29/22 |
Michaelson Jennifer | See Remarks See Remarks | Nov 25 | Sell | 13.3 | 4,000 | 53,200 | 53,031 | 11/29/22 |
Michaelson Jennifer | Chief Development Of.. Chief Development Officer | Aug 08 | Option | 4.3 | 1,385 | 5,956 | 54,416 | 08/09/22 |
Michaelson Jennifer | Chief Development Of.. Chief Development Officer | Aug 08 | Sell | 15.01 | 1,385 | 20,789 | 53,031 | 08/09/22 |
F2 Vision SCS | 10% Owner 10% Owner | Aug 02 | Sell | 14.21 | 49,910 | 709,221 | 1,255,963 | 08/04/22 |
Michaelson Jennifer | Chief Development Of.. Chief Development Officer | Jul 25 | Option | 4.3 | 8,000 | 34,400 | 61,031 | 07/26/22 |
Michaelson Jennifer | Chief Development Of.. Chief Development Officer | Jul 25 | Sell | 14.51 | 8,000 | 116,080 | 53,031 | 07/26/22 |
Savill Corrine | Acting Chief Busines.. Acting Chief Business Officer | Jul 11 | Sell | 13.59 | 40,000 | 543,600 | 169,615 | 07/12/22 |
Jovan-Embiricos Morana | 10% Owner 10% Owner | Jun 24 | Option | 4.3 | 140,374 | 603,608 | 252,881 | 06/28/22 |
F2 Bioscience I 2017 Ltd | 10% Owner 10% Owner | Jun 21 | Sell | 12.82 | 101,903 | 1,306,396 | 537,392 | 06/23/22 |
BVF PARTNERS L P/IL | 10% Owner 10% Owner | Jun 01 | Buy | 11 | 751,396 | 8,265,356 | 364,161 | 06/03/22 |
F2 Vision SCS | 10% Owner 10% Owner | May 12 | Sell | 10.23 | 418,738 | 4,283,690 | 1,305,873 | 05/16/22 |
BVF PARTNERS L P/IL | 10% Owner 10% Owner | May 12 | Buy | 9.11 | 1,109,900 | 10,111,189 | 319,415 | 05/16/22 |
BVF PARTNERS L P/IL | 10% Owner 10% Owner | Apr 01 | Buy | 10.75 | 276,000 | 2,967,000 | 2,196,240 | 04/05/22 |